Locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after first-line treatment has a poor prognosis. Recent randomized clinical trials (RCTs) have demonstrated survival benefits of alternative treatments to docetaxel. | Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer A systematic review and network meta-analysis